Cosmos Holdings

COSM

Market cap $19M

Science-first nutraceutical platform: Every "18" product must clear three criteria before reaching market - a patented ingredient, peer-reviewed clinical evidence, and the exact dose studied in clinical trials; a bar the vast majority of the supplement industry cannot meet Three products introduced, $7.8 billion addressable market: Noor18™, Liv18™, and Cur18™ - targeting healthy aging & beauty, liver & metabolic support, and inflammation & mobility across three of the fastest-growing health categories in the U.S. Institutional-grade scientific standard: Patented ingredients, published randomized controlled trials, exact clinical dosing - built to the standard of institutional science, not marketing Compounding platform value, 18 clinically validated products targeted: Each new "18" product retroactively strengthens every existing one - the portfolio becomes more valuable with every addition CHICAGO, IL / ACCESS Newswire / April 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the U.S. introduction of the "18 Series" - a premium nutraceutical platform designed to meet growing consumer demand for clinically validated health solutions. 1. The 18 Series - Overview Cosmos Health Inc. is executing a disciplined, science-first strategy to build the what we believe to be most credible clinical supplement portfolio in the United States.

Phase 1 complete: product development, packaging, and initial commercial setup finalized ahead of schedule Production commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufacturing - mitigating tariff risk $5M+ projected annual revenue: Liv18™ expected to generate over $5 million annually at approximately 75% gross margins Direct-to-consumer model: scalable DTC strategy with targeted advertising and disciplined capital allocation Early U.S. traction confirmed: commercial indicators from existing products shaping revenue expectations and go-to-market strategy CHICAGO, IL / ACCESS Newswire / April 20, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided a commercial and financial update on Liv18™, its clinically validated liver health supplement, as the Company accelerates its expansion across the United States. The Company has successfully completed Phase 1 execution for Liv18™ (defined as product development, packaging, and initial commercial setup) ahead of schedule.

Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts. Derived predominantly from turmeric (~98.5%), maintaining a composition closer to the natural profile of the plant.

CHICAGO, IL / ACCESS Newswire / April 16, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the continued integration of artificial intelligence (AI) across its operations, reflecting ongoing investments aimed at enhancing efficiency, reducing costs, improving customer experience, and driving sales growth. AI is becoming an increasingly important component of Cosmos Health's operating model and a key enabler across multiple areas of its business, with initial efficiency gains already being realised.

Scaled contract manufacturing division, securing long-term agreements for over 12 million units Expanded Sky Premium Life portfolio by 60 SKUs and accelerated global expansion, securing purchase orders for over 300,000 units across new markets Advanced R&D pipeline, securing patented anticancer drugs, multiple AI-driven patent filings, and CCX0722 weight management product entering final development Secured $300 million financing facility to launch digital asset treasury strategy CEO Greg Siokas increased ownership by over 3.3 million shares, reinforcing deep insider conviction Strong momentum continues into 2026 with record growth across all core segments and continued U.S. expansion underway CHICAGO, IL / ACCESS Newswire / April 15, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today reported financial results for the full year ended December 31, 2025, delivering the strongest annual revenue performance in the Company's history. Full Year 2025 Financial Highlights Performance was marked by all-time high revenue, significant gross profit expansion, and margin improvement, driven by strong performance across core business segments, including scaling the contract manufacturing division at Cana Laboratories, increased volumes in the CosmoFarm wholesale distribution business supported by an expanded pharmacy network, solid sales growth through Decahedron in the United Kingdom, and the global expansion of proprietary brands, including Sky Premium Life and C-Scrub.

CHICAGO, IL / ACCESS Newswire / April 13, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has received a new purchase order for 60,000 units of its Sky Premium Life products from Pharmalink under the existing exclusive distribution agreement for the United Arab Emirates (UAE) market. This marks the third consecutive purchase order from Pharmalink, bringing cumulative orders to 270,000 units since the partnership's inception in June 2024.

CHICAGO, IL / ACCESS Newswire / April 10, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today confirmed that the ongoing conflict in Iran and broader Middle East geopolitical tensions have not had a material impact on the Company's operations, supply chain, or business performance. The Company also noted continued record revenue momentum and reaffirmed that its U.S. expansion, including the rollout of NOOR collagen, remains on track.

Powered by BergacynFF ® , the only patented botanical blend clinically demonstrated to reduce liver fat accumulation and support healthy body weight in two independent randomized controlled trials. CHICAGO, IL / ACCESS Newswire / April 8, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the planned Q2 2026 U.S. launch of Liv18™, a next-generation liver health supplement powered by BergacynFF®, the only patented botanical blend clinically demonstrated to reduce liver fat accumulation and support healthy body weight in two independent randomized controlled trials.

CHICAGO, IL / ACCESS Newswire / April 1, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that C-Scrub Wash 4%, manufactured by its wholly owned subsidiary Cana Laboratories S.A., has successfully completed testing under EN 12791:2016+A1:2017, the European standard for surgical hand disinfection.

Continues to deliver record revenue and improving operating metrics Significant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75% NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibility Evaluating potential monetization of non-core assets to support more efficient capital allocation accelerate strategic investments address the current valuation disconnect, including options such as share repurchases Recent geopolitical turmoil has had a negligible impact on the Company's operations, with record-breaking growth continuing at a strong pace To issue guidance update following the release of fourth quarter and full-year 2025 results Analyst coverage initiated by Zacks Small-Cap Research with a valuation of $4.50 per share CHICAGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided a corporate update and announced that it intends to issue updated operational, strategic, and financial guidance following the release of its fourth quarter and full-year 2025 financial results. Record Operating Momentum Cosmos Health continues to deliver record revenue and gross profit while improving operating metrics, reflecting disciplined execution across all core divisions.